Genentech Inc.
Division of Roche
www.gene.com
Latest From Genentech Inc.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention
UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.
EMA OKs Seven New Drugs But Delivers Another Blow To Emmaus
Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe
Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA
Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gastrointestinal
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Ophthalmic
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Roche
- Senior Management
-
Alexander Hardy, CEO
Ed Harrington, CFO
Levi J Garraway, CMO & Head, Global Product Dev. - Contact Info
-
Genentech Inc.
Phone: (650) 225-1000
1 DNA Way
S. San Francisco, CA 94080
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice